Holen Sie sich die Stockscreener-App
322.62
0.53%
-1.725
Schlusskurs vom Vortag:
$324.34
Offen:
$324.46
24-Stunden-Volumen:
166.48K
Relative Volume:
0.50
Marktkapitalisierung:
$12.71B
Einnahmen:
$1.45B
Nettoeinkommen (Verlust:
$171.05M
KGV:
74.23
EPS:
4.3459
Netto-Cashflow:
$212.73M
1W Leistung:
+0.78%
1M Leistung:
+1.20%
6M Leistung:
-1.34%
1J Leistung:
+29.56%
1-Tages-Spanne:
$321.97
$324.46
1-Wochen-Bereich:
$320.09
$324.64
52-Wochen-Spanne:
$221.26
$362.41
Penumbra Inc Stock (PEN) Company Profile
Firmenname
Penumbra Inc
Sektor
Branche
Telefon
(510) 995-2486
Adresse
ONE PENUMBRA PLACE, ALAMEDA, CA
Compare PEN vs ABT, MDT, SYK, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PEN
Penumbra Inc
|
322.62 | 12.71B | 1.45B | 171.05M | 212.73M | 4.3459 |
ABT
Abbott Laboratories
|
98.61 | 170.62B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
93.39 | 119.46B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
294.48 | 112.95B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
44.14 | 63.97B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.72 | 50.56B | 6.30B | 1.07B | 1.09B | 1.8406 |
Penumbra Inc Stock (PEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-18 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-12-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-11-18 | Eingeleitet | Wells Fargo | Underweight |
| 2025-10-08 | Hochstufung | Needham | Hold → Buy |
| 2025-09-02 | Eingeleitet | Evercore ISI | Outperform |
| 2025-03-14 | Eingeleitet | BofA Securities | Buy |
| 2025-01-21 | Eingeleitet | UBS | Buy |
| 2024-12-17 | Eingeleitet | Oppenheimer | Outperform |
| 2024-12-11 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-09-18 | Eingeleitet | Stifel | Buy |
| 2024-09-03 | Eingeleitet | Leerink Partners | Outperform |
| 2024-07-31 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-07-31 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-02-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-09-06 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-03-29 | Herabstufung | Needham | Buy → Hold |
| 2023-01-30 | Eingeleitet | Piper Sandler | Overweight |
| 2022-11-04 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-10-05 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-09-09 | Hochstufung | Needham | Hold → Buy |
| 2022-07-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-04-19 | Eingeleitet | Deutsche Bank | Buy |
| 2022-03-08 | Eingeleitet | Needham | Hold |
| 2021-09-16 | Eingeleitet | Truist | Buy |
| 2021-06-04 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-12-16 | Herabstufung | BTIG Research | Buy → Neutral |
| 2020-10-07 | Fortgesetzt | Canaccord Genuity | Buy |
| 2020-09-29 | Eingeleitet | BTIG Research | Buy |
| 2020-09-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-06-13 | Bestätigt | BofA/Merrill | Buy |
| 2019-05-30 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-05-21 | Eingeleitet | William Blair | Outperform |
| 2018-10-29 | Fortgesetzt | BofA/Merrill | Buy |
| 2018-10-08 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2018-02-21 | Eingeleitet | William Blair | Outperform |
| 2018-01-02 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2015-11-30 | Bestätigt | Canaccord Genuity | Buy |
| 2015-10-13 | Eingeleitet | Wells Fargo | Outperform |
Alle ansehen
Penumbra Inc Aktie (PEN) Neueste Nachrichten
Penumbra Says FDA Clears CAVT Technology for Deep Vein Thrombosis - marketscreener.com
FDA clears Penumbra’s CAVT technology for DVT treatment - Investing.com
Penumbra's CAVT Technology Receives FDA Clearance for the Treatment of Deep Vein Thrombosis (DVT) - StreetInsider
Penumbra wins FDA clearance for DVT treatment technology - StreetInsider
Form 4 Penumbra Inc: Shruthi Narayan (President) For: 15 October By Investing.com - Investing.com Nigeria
Penumbra stock has November 4 earnings date with USD 401.41 million forecast - ad-hoc-news.de
MarketBeat cites USD 367.07 average target for Penumbra stock - ad-hoc-news.de
Could STORM-PE Data Change Penumbra (NASDAQ:PEN) Story? - Kalkine Media
Penumbra (PEN) Clinical Data Puts Its Valuation Back In Focus - Yahoo Finance
Penumbra presented STORM-PE data while Penumbra stock trades at EUR 281.30 - AD HOC NEWS
Penumbra (BSP:P2NB34) Total Tax Payable : R$ Mil (As of Jun. 2026) - GuruFocus
Operating cash flow per share of Penumbra, Inc. – HAN:0P8 - TradingView
New STORM-PE Data Demonstrate Correlation Between Clinical Assessments and Real-world Functional Recovery Captured Through Wearable Technology in Patients with Pulmonary Embolism - BioSpace
Penumbra stock gets fresh STORM-PE data catalyst - AD HOC NEWS
Behavioral Patterns of PEN and Institutional Flows - Stock Traders Daily
Penumbra (PEN) Highlights Wearable Device Data Linking Activity to Recovery in Pulmonary Embolism Trial - GuruFocus
New STORM-PE Data Demonstrate Correlation Between Clinical Assessments and Real-world Functional Recovery Captured Through Wearable Technology in Patients with Pulmonary Embolism - PR Newswire
In a lung-clot study, fitness-watch steps lined up with clinic walking tests - Stock Titan
New STORM-PE Data Demonstrate Correlation Between Clinical Assessments and Real-world Functional Recovery Captured Through Wearable Technology in Patients with Pulmonary Embolism - Nasdaq
Penumbra stock reports 14.9 percent revenue growth as EPS misses - AD HOC NEWS
Boston Scientific keeps Penumbra deal on track as Penumbra stock costs EUR 284.00 - AD HOC NEWS
Penumbra, Inc. (PEN) Stock forecasts - Yahoo Finance UK
Revenue per share of Penumbra, Inc. – HAN:0P8 - TradingView
Penumbra stock breaks below 50-day average - AD HOC NEWS
IART vs. PEN: Which Stock Is the Better Value Option? - Zacks Investment Research
Current ratio of Penumbra, Inc. – HAN:0P8 - TradingView
Average basic shares outstanding of Penumbra, Inc. – HAN:0P8 - TradingView
Penumbra, Inc. (PEN) Stock Forecasts - Yahoo Finance
IART or PEN: Which Is the Better Value Stock Right Now? - Zacks Investment Research
The Technical Signals Behind (PEN) That Institutions Follow - news.stocktradersdaily.com
Anaconda Biomed raises $56m for catheter portfolio’s advance - Yahoo Finance
Penumbra, Inc. (PEN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Penumbra, Inc. (PEN) Stock Forecasts - Yahoo Finance
ETFs Investing in Penumbra, Inc. Stocks - TradingView
Penumbra Inc. stock trades near 317 dollars as investors weigh growth and valuation - AD HOC NEWS
Penumbra Inc. stock holds near 315 dollars as growth expectations stay high - AD HOC NEWS
Penumbra Stock Price Forecast. Should You Buy PEN? - StockInvest.us
Reasons to Retain Penumbra Stock in Your Portfolio for Now - Yahoo Finance
Reasons to Retain Penumbra Stock in Your Portfolio for Now - Eastern Progress
Penumbra, Inc. (PEN) Stock Analysis: Navigating Growth With A 13.88% Potential Upside - DirectorsTalk Interviews
Price to earnings forward of Penumbra, Inc. – NYSE:PEN - TradingView
Penumbra, Inc. (PEN): Growth Potential Amidst Analyst Consensus And Market Dynamics - directorstalkinterviews.com
Discipline and Rules-Based Execution in PEN Response - Stock Traders Daily
BSP:P2NB34 Enterprise Value: R$-100 Mil | Fairly Valued - GuruFocus
BSP:P2NB34 Shareholder Yield %: 0.05% | Fairly Valued - GuruFocus
BSP:P2NB34 Revenue: R$7,963 Mil | Fairly Valued - GuruFocus
BSP:P2NB34 GF Value: R$57.41 | Fairly Valued - GuruFocus
BSP:P2NB34 ROCE %: 10.74% | Fairly Valued - GuruFocus
Penumbra (BSP:P2NB34) Loans Receivable : R$0 Mil (As of Jun. 2026) - GuruFocus
Penumbra Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Finanzdaten der Penumbra Inc-Aktie (PEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Penumbra Inc-Aktie (PEN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Grewal Harpreet | Director |
Apr 02 '26 |
Proposed Sale |
328.22 |
100 |
32,822 |
0 |
| Yuen Maggie | Chief Financial Officer |
Mar 02 '26 |
Sale |
342.30 |
2,432 |
832,474 |
18,353 |
| MAGGIE YUEN | Officer |
Mar 02 '26 |
Proposed Sale |
342.30 |
2,432 |
832,474 |
0 |
| Grewal Harpreet | Director |
Jan 06 '26 |
Proposed Sale |
312.64 |
186 |
58,151 |
0 |
| Grewal Harpreet | Director |
Jan 06 '26 |
Sale |
312.64 |
186 |
58,151 |
8,230 |
| THOMAS WILDER | Director |
Jan 02 '26 |
Proposed Sale |
310.72 |
186 |
57,794 |
0 |
| Wilder Thomas | Director |
Jan 02 '26 |
Sale |
310.72 |
186 |
57,794 |
0 |
| Bose Arani | Director |
Dec 11 '25 |
Sale |
308.82 |
15,000 |
4,632,292 |
258,462 |
| Roberts Johanna | EVP, Gen. Counsel & Secretary |
Dec 05 '25 |
Sale |
300.13 |
300 |
90,039 |
63,836 |
| Grewal Harpreet | Director |
Dec 02 '25 |
Sale |
292.98 |
100 |
29,298 |
8,416 |
0.03%
1.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):